Medical Device CRO: How to Qualify Your Clinical Partner

March 30, 2024

Introduction

In the highly regulated and competitive world of medical device development, the choice of a Clinical Research Organization (CRO) is more than a business decision—it’s a strategic partnership crucial to success. A qualified Medical Device CRO brings invaluable expertise in clinical investigations, regulatory navigation, and market entry strategies, acting as a linchpin for the development and approval processes. As the medical device industry grapples with stringent regulations, such as the EU MDR 2017/745, and evolving technological advancements, the stakes for choosing the right Medical Device CRO have never been higher. This article delves into how medical device companies can qualify their CRO partners, ensuring they align with their benchmark of excellence and are fully equipped to navigate the complexities of bringing innovative medical solutions to market.

Qualifying Your Medical Device CRO Partner: A Strategic Evaluation Framework

Choosing the right Clinical Research Organization (CRO) is pivotal for medical device manufacturers seeking to navigate the intricacies of clinical investigations, regulatory compliance, and market success. The process of qualifying a Medical Device CRO goes beyond simple service comparisons; it requires a strategic evaluation framework that ensures the selected partner is not only capable but also highly aligned with the company’s specific needs and goals. This framework should consider a variety of critical factors, including expertise in clinical operations, regulatory acumen, quality assurance capabilities, and a proven track record of success in the medical device field. By adopting a holistic and rigorous approach to evaluating potential CRO partners, companies can foster successful collaborations that are essential for achieving their project milestones and long-term objectives.

Criteria for Excellence: What to Look for in a Medical Device CRO

When selecting a Medical Device Clinical Research Organization (CRO) for medical device development, it’s essential to employ a strategic evaluation framework that encompasses various critical criteria. This rigorous approach ensures that the CRO is not only competent but also perfectly aligned with the specific needs and goals of your project. Here are the key criteria to consider:

1. Expertise in Clinical Operations

Look for a Medical Device CRO with a proven track record in managing and executing clinical investigations specific to medical devices. This includes experience with ISO 14155 and adherence to Good Clinical Practice (GCP), indicating their capability to handle the nuances of medical device clinical investigations.

2. Regulatory Strategy and Compliance

The ideal Medical Device CRO should demonstrate in-depth knowledge of global regulatory requirements, including the EU MDR 2017/745, and FDA regulations. Their expertise should cover strategic planning, submission processes, and the ability to navigate regulatory pathways efficiently.

3. Quality Assurance and Management Systems

Quality assurance is critical in medical device development. The CRO should have robust Quality Management Systems (QMS) in place, compliant with ISO 13485 and capable of ensuring the highest standards are met throughout the project lifecycle.

4. Medical Writing and Documentation

Exceptional medical writing capabilities are essential for clear, compliant, and persuasive documentation. This includes clinical evaluation reports, regulatory submissions, and technical documentation necessary for approval processes.

5. Data Management and Biostatistics

Competence in data management and statistical analysis is vital for interpreting clinical investigation data accurately. The Medical Device CRO should offer sophisticated methods for data collection, management, and analysis, supporting regulatory submissions and market claims.

6. Project Management

Effective project management ensures that clinical investigations are completed on time, within budget, and to the required quality standards. Look for a CRO with a strong project management framework, emphasizing communication, transparency, and stakeholder engagement.

7. Adaptability and Customized Solutions

Each medical device project is unique, requiring tailored approaches. A qualified Medical Device CRO should demonstrate flexibility and the ability to provide customized solutions that align with the specific challenges and goals of your project.

8. Reputation and Track Record

Finally, consider the CRO’s reputation within the industry and its track record of success. Testimonials, case studies, and references from past clients can provide valuable insights into their capabilities and reliability.

By meticulously evaluating potential CRO partners against these criteria, medical device companies can ensure they select a partner that will contribute significantly to the success of their projects.

The right CRO is a crucial ally in the complex journey from concept to market, providing expertise, support, and guidance every step of the way

The Benefits of Partnering with an Excellent Medical Device CRO

Choosing a Clinical Research Organization (CRO) that aligns with the strategic evaluation framework and exemplifies the criteria for excellence, such as MDx, brings manifold benefits to medical device companies. These advantages not only streamline the pathway from development to market but also ensure compliance, enhance quality, and optimize outcomes. Here are the key benefits of such a partnership:

Enhanced Efficiency and Time-to-Market

A CRO that excels in project management, clinical operations, and regulatory strategy can significantly expedite the development process. By effectively navigating clinical investigations and regulatory approvals, an excellent CRO reduces time-to-market, enabling quicker patient access and competitive advantage.

Rigorous Regulatory Compliance and Approval Success

Expertise in global regulatory landscapes is crucial for navigating the complex approval processes. A top-tier CRO ensures that all aspects of the development process, from clinical evaluations to technical documentation, meet the stringent standards set by regulatory bodies. This comprehensive understanding of regulatory requirements minimizes the risk of delays and rejections, facilitating smoother market entry.

Quality Assurance Across the Development Lifecycle

Quality assurance is embedded in the DNA of an excellent Medical Device CRO. Through robust Quality Management Systems (QMS) and adherence to international standards such as ISO 13485, a CRO ensures that every stage of development meets the highest quality standards. This commitment to quality not only supports regulatory compliance but also enhances the safety, efficacy, and reliability of the medical device.

Data Integrity and Scientific Rigor

The management and analysis of clinical investigation data are critical for substantiating claims and supporting regulatory submissions. Partnering with a CRO skilled in data management and biostatistics ensures the integrity and scientific rigor of investigation data, bolstering the case for approval and market acceptance.

Tailored Solutions and Flexibility

Each medical device project comes with its unique challenges and requirements. An excellent Medical Device CRO offers the adaptability and customized solutions necessary to address specific project needs effectively. This flexibility ensures that innovative approaches are applied to overcome obstacles and achieve project goals.

Access to Expertise and Global Networks

A CRO with a wealth of expertise and a global network can provide invaluable resources and insights throughout the development process. From subject matter experts to connections with regulatory bodies and clinical sites, this access facilitates smoother project execution and opens doors to opportunities and collaborations.

Conclusion

In the competitive and highly regulated world of medical device development, partnering with the right Medical Device CRO is not just a choice—it is a strategic imperative. By adhering to a strategic evaluation framework and selecting a CRO that embodies the criteria for excellence, medical device companies can navigate the complexities of development, regulatory approval, and market entry with confidence and efficiency.

MDx serves as a prime example of what to look for in a clinical research partner. With its comprehensive services, unparalleled expertise, and commitment to quality and success, MDx stands ready to support medical device companies in bringing their innovations to market.

For those in the medical device industry seeking a partner that meets these high standards, we invite you to learn more about how MDx can contribute to the success of your projects. Reach out for a consultation or more information on our full-service offerings and take the first step towards realizing your development and market aspirations.

Looking for a qualified medical device CRO?

Explore MDx’s services

Frequently Asked Questions about Medical Device CRO

What is a medical device CRO and what do they do?

A medical device CRO (Contract Research Organization) is a specialized partner that supports medical device manufacturers throughout the clinical and regulatory lifecycle. Unlike pharmaceutical CROs, a medical device CRO is experienced in the specific frameworks that govern device development — ISO 14155 for clinical investigations, EU MDR 2017/745 for regulatory compliance, and MEDDEV 2.7/1 Rev 4 for clinical evaluation. Their services typically span clinical investigation management, Clinical Evaluation Reports (CERs), Post-Market Clinical Follow-Up (PMCF) studies, technical documentation, and regulatory strategy. The right CRO acts as an extension of your team — not just a vendor.

How do I know if a medical device CRO is qualified to handle my project?

Start with four non-negotiables: ISO 14155 compliance, demonstrated experience with your device class (Class I, IIa, IIb, or III), knowledge of the relevant regulatory pathway (EU MDR, FDA, UKCA), and a verifiable track record with similar projects. Ask for case studies, reference clients, and — critically — ask about their Notified Body relationships. A CRO that has worked directly with BSI, TÜV SÜD, or other Notified Bodies understands what auditors actually look for, which dramatically reduces the risk of queries and delays

What questions should I ask a medical device CRO before signing a contract?

The most important questions to ask are: What is your experience with devices in my classification and therapeutic area? Can you show examples of CERs or technical documentation you’ve produced that passed Notified Body review? Who specifically will be working on my project — and what are their qualifications? How do you manage timelines and communicate progress? What happens if we receive a Notified Body query — is response management included? The answers reveal whether you’re dealing with a capable team or a generalist firm that will learn on your budget

What’s the difference between a medical device CRO and a regulatory consultant?

A regulatory consultant typically provides advisory services — guidance on strategy, documentation review, or gap assessments. A full-service medical device CRO goes further: they own and execute deliverables, manage clinical investigations end-to-end, produce submission-ready documentation, and take accountability for outcomes. For complex projects involving clinical evidence generation, PMCF studies, or Class IIb/III certification, a CRO’s integrated clinical-regulatory capability is essential. For targeted, defined tasks, a consultant may suffice. Many companies use both — a CRO for execution and a consultant for independent review

How long does it take to qualify a medical device CRO?

A thorough CRO qualification process typically takes 4–8 weeks and should include a capability assessment, review of SOPs and QMS documentation, reference checks, and a project-specific scoping discussion. Rushing this process is one of the most common and costly mistakes in medical device development — a misaligned CRO partnership can add 6–12 months to your timeline. If a CRO cannot provide clear documentation of their quality systems and past outcomes, that itself is a disqualifying signal

How does MDx approach Clinical Evaluation Plans (CEPs) for medical devices?

MDx develops CEPs in alignment with MDCG 2020-13 guidance and EU MDR Annex XIV requirements. Each CEP defines the intended purpose, clinical claims, equivalence justification (where applicable), literature search methodology, and acceptance criteria before evidence gathering begins — ensuring the clinical evaluation is structured, defensible, and proportionate to the device’s risk class. A well-constructed CEP significantly reduces Notified Body queries during the CER review stage.

Written by:

David Tomé

President

Clinical research leader and MedTech entrepreneur with deep expertise in medical devices, IVDs & precision medicine, with global study experience.

Industry Insights & Regulatory Updates

Advanced digital health technology showcasing human body and medical device integration for MedTech innovation.

EU AI Act and Medical Devices: What SaMD Developers Need to Know (2026)

EU MDR 2017/745 for Dental Devices: Complete Guide (2026)

FDA QMSR: How the 2026 Regulation Shift Transforms MDSAP Audits and FDA Compliance Inspections

IVDR Annex XIV clinical performance study a complete guide

IVDR Annex XIV Performance Studies for Companion Diagnostics: A Step-by-Step Guide 2026

MDR Annex XVI: Regulating Products Without an Intended Medical Purpose Under the MDR

Understanding MDCG 2021-6 Rev. 1: A Comprehensive Guide for Clinical Investigations under EU MDR

March 16, 2024

The Medical Device Regulation (MDR) 2017/745 has transformed the EU’s regulatory landscape for medical devices. It aims to boost patient safety and transparency. The regulation sets strict criteria for clinical investigations. In this context, MDCG 2021-6 Rev. 1 is key. Issued by the Medical Device Coordination Group (MDCG), it underwent a revision in December 2023.

This update offers valuable insights. It addresses common questions about clinical investigations under MDR. The impact is wide-reaching. Manufacturers, sponsors, competent authorities, research centers, ethics committees, legal representatives, and CROs are all affected. This guide explores MDCG 2021-6 Rev. 1’s vital aspects. Moreover, it highlights its implications for these stakeholders.

Introduction to MDCG 2021-6 Rev. 1

MDCG 2021-6 Rev.1 is a cornerstone document for those embarking on clinical investigations of devices within the scope of the Medical Device Regulation (EU) 2017/745 (MDR). Designed for sponsors, this evolving guide may expand with more questions and answers over time. It clarifies the use of the term ‘device’ in line with MDR. This includes medical devices, their accessories, and specific products listed in Annex XVI.

The guide also standardizes the definition of “clinical investigation.” It aligns with Article 2(45) of the MDR, focusing on investigations aimed at assessing a device’s safety or performance. Moreover, it introduces the broader concept of “clinical study.” This encompasses a range of research activities within medical science. It includes clinical trials of medicines, device investigations, and in vitro diagnostic studies. These elements are vital for understanding the full scope of clinical research.

This document touches on key topics crucial for navigating the regulatory landscape:

Proof of Concept Studies: Offering insights into the initial stages of device development.
Article 82 Clinical Studies: Clarifying the scope of broader research activities under MDR.
Pilot Stage Investigations: Defining early feasibility and its regulatory implications.
Regulatory Pathways: Shedding light on navigating clinical investigations amidst the interplay of MDR, the Clinical Trial Regulation (CTR), and local laws.
Combined Trials: Addressing the complexities of studies involving both medicinal products and medical devices.
Invasive or Burdensome Considerations: Guiding sponsors on ethical and participant safety considerations.
Usability Testing: Outlining when such tests are considered clinical investigations.
Retrospective Testing: Distinguishing between prospective data collection and the analysis of existing data.
Submissions and Modifications: Offering guidance on navigating regulatory submissions and changes during the clinical investigation process.
Legal Representation: Emphasizing the role of legal representatives in ensuring compliance.

Some of the Key Highlights of MDCG 2021-6 Rev. 1

MDCG 2021-6 Rev. 1 offers an in-depth exploration into the clinical investigations aspects under the Medical Device Regulation (EU) 2017/745 (MDR). This document is instrumental in bridging the regulatory gaps and ensuring a harmonized approach across the European Union. Here are the refined key highlights based on the updated request:

Regulatory Pathways and Documentation

The document elaborates on navigating the regulatory landscape for conducting clinical investigations. It includes guidance on choosing the correct regulatory pathway, be it for a novel device entering early-stage clinical investigation or for further assessment of a CE-marked device. Detailed documentation requirements facilitate sponsors in preparing comprehensive applications, streamlining the approval process.

Legal Representative’s Role and Responsibilities

The document provides clarity on the responsibilities of the sponsor’s legal representative, which is pivotal for non-EU manufacturers. It underlines the need for a legal representative within the EU to ensure compliance with MDR requirements. This representative acts as a point of contact between the non-EU sponsor and the EU regulatory authorities, facilitating the submission and communication processes.

Substantial Modifications

Understanding what constitutes a substantial modification is crucial for the continuity and compliance of clinical investigations. MDCG 2021-6 Rev. 1 details the criteria for identifying substantial modifications that could impact the safety, health, or rights of subjects, or the reliability and robustness of the clinical data.

This guidance aids sponsors in navigating the process for notifying competent authorities about such modifications, ensuring that the integrity and validity of the investigation are maintained.

Relationship with the CTR, Combined Trials, and Combination Products

The document delves into the interplay between medical device regulations and the Clinical Trials Regulation (CTR), particularly in the context of combined trials and combination products. It highlights the importance of navigating both regulatory frameworks when a study involves medical devices and medicinal products. This includes guidance on conducting clinical studies that collect data for both devices and associated medicinal products, ensuring compliance with the MDR and CTR. The document’s insights into handling combination products—where devices and medicinal substances are integrated—are crucial for sponsors planning such studies.

Clarifications on Specific Aspects of Clinical Investigations

MDCG 2021-6 Rev. 1 sheds light on several nuanced areas of clinical investigations:

Usability Testing: It clarifies when usability tests are considered clinical investigations.
Invasiveness Considerations: The document defines what constitutes invasive procedures and the implications for clinical investigations, emphasizing the importance of assessing the invasiveness level when planning studies.
Retrospective Studies: Insights are provided on the role of retrospective studies within clinical investigations, delineating when such studies fall under the scope of clinical investigation definitions and how they contribute to clinical evaluations.
Proof of Concept Studies: Guidance on conducting proof of concept studies is highlighted, including their significance in the early stages of device development and their regulatory considerations under the MDR.

In-Depth Highlights of MDCG 2021-6 Rev. 1 for Specialized Clinical Investigations

Proof of Concept Studies according MDCG 2021-6 Rev. 1

Proof of Concept (PoC) studies are instrumental in the nascent phases of medical device development. These studies aim to demonstrate the feasibility and potential clinical benefits of a device, laying the groundwork for subsequent development stages. MDCG 2021-6 Rev. 1 provides comprehensive guidance on PoC studies, emphasizing their critical role in validating device concepts and navigating the regulatory framework of the MDR.

PoC studies serve as a foundational element in device development, enabling sponsors to assess a device’s early clinical viability and address potential design modifications before advancing to more comprehensive clinical trials. The guidance from MDCG 2021-6 Rev. 1 ensures that these studies are conducted within a framework that prioritizes patient safety, scientific validity, and regulatory compliance.

By focusing on detailed planning, ethical conduct, and adherence to specified regulatory pathways, PoC studies under the guidance of MDCG 2021-6 Rev. 1 facilitate a smoother transition through the early stages of device development.

MDCG 2021-6 Rev. 1 delineates the regulatory pathways essential for conducting PoC studies that support the conformity assessment of the device under investigation. It specifies the need for a meticulously detailed Clinical Investigation Plan (CIP), ensuring that PoC studies are grounded in solid scientific rationale and ethical considerations. This guidance is particularly highlighted in:

Question 7, which discusses the regulatory pathways for clinical investigations aimed at supporting device conformity assessments.
Question 11, focusing on the investigational use of CE-marked devices for new potential applications or further PoC studies.
Question 8, which identifies clinical investigations considered at the pilot stage, setting the stage for PoC studies.
Question 9, providing a roadmap for conducting early feasibility and first-in-human studies under the MDR, underscoring the importance of thorough risk assessment and ethical considerations.

Combined Trials

Combined Trials represent a pivotal area of focus within the regulatory landscape of clinical investigations, particularly when these involve both medical devices and medicinal products.

The MDCG 2021-6 Rev. 1 and MDCG 2022-10 documents offer a comprehensive overview of the complexities and regulatory pathways for conducting such trials, highlighting the necessity for compliance with the Medical Device Regulation (EU 2017/745, MDR) and the Clinical Trials Regulation (EU 536/2014, CTR), as well as with the In Vitro Diagnostic Regulation (EU 2017/746, IVDR).

Questions 15 and 16 in MDCG 2021-6 Rev. 1 and the detailed guidance in MDCG 2022-10 illuminate the pathway for combined trials involving medical devices and medicinal products. This guidance is crucial for sponsors planning studies that bridge the gap between medical devices and pharmaceuticals, offering clear directives on navigating combined trials.
The concept of “combined trial” is further elaborated to include simultaneous investigation of a medicinal product (clinical trial authorized under the CTR) and an IVD (clinical performance study), subject to the requirements of both the CTR and IVDR.
Sponsors are encouraged to thoroughly understand and comply with both MDR/IVDR and CTR requirements, ensuring that all aspects of the combined trials are adequately addressed.

Usability Studies

Usability studies are paramount in ensuring that medical devices meet the highest standards of safety and performance through effective user interface design. The MDCG 2021-6 Rev. 1 document, alongside the EN 62366-1:2015 standard, provides comprehensive guidance on when and how usability studies are considered within the scope of clinical investigations under the MDR.

It emphasizes the crucial role of usability studies in integrating user feedback into the device design and development processes. This aligns with the focus of EN 62366-1:2015 on user interface characteristics that foster both safety and user satisfaction, highlighting the importance of these studies in enhancing device usability and overall patient care.

Usability testing evaluates how well users can interact with a device within specified environments, aiming to enhance the user interface to promote performance, safe, and satisfying use.

Question 17 of MDCG 2021-6 Rev. 1 clarifies when usability studies are regarded as clinical investigations under the MDR. The classification hinges on the study’s scope, purpose, and the extent to which users are exposed to the device.
Usability testing that exposes users to device-related risks or where poor usability could impact patient or user safety is more likely to fall under the definition of a clinical investigation. Manufacturers must document their rationale for classifying a usability test as outside the scope of a clinical investigation when human subjects are involved.
Manufacturers should strategically design usability tests to limit human exposure to risks before investigating device performance and safety in clinical investigations.
Documentation of usability considerations, as part of the technical documentation, is critical. This includes justifying why certain usability tests do not constitute clinical investigations, ensuring compliance with both MDCG 2021-6 Rev. 1 guidance and EN 62366-1:2015 requirements.

Invasive or Burdensome Considerations in MDCG 2021-6 Rev. 1

Question 13 is particularly relevant for ensuring the ethical conduct and safety of participants in clinical investigations. It delves into what is considered burdensome or invasive, guiding sponsors in designing studies that minimize discomfort or risk to participants. This question is vital for maintaining ethical standards and participant welfare in both medical device and in vitro diagnostic studies under IVDR.

Impact on Medical Device Stakeholders

The MDCG 2021-6 Rev. 1 document significantly influences the medical device sector. It offers pivotal guidance that extends well beyond the regulatory framework to affect various stakeholders involved in the lifecycle of a medical device within the European Union.

Manufacturers and Sponsors

Manufacturers and sponsors find in MDCG 2021-6 Rev. 1 an essential roadmap. This guidance provides clarity on regulatory requirements, helping to streamline clinical investigations, mitigate risks, and shorten the time-to-market for innovative solutions.

Strategic Planning and Execution: The document outlines regulatory pathways for different types of clinical investigations, facilitating better planning and execution.
Risk Management: Emphasizes the importance of safety reporting and ethical considerations, aiding in the development of comprehensive risk management strategies.

Competent Authorities and Ethics Committees

Competent authorities and ethics committees are crucial in the regulatory oversight of medical devices. MDCG 2021-6 Rev. 1 enhances their ability to assess and ensure compliance with the MDR, promoting a unified application across the EU.

Streamlined Review Processes: Provides clear guidelines that support more efficient review and approval processes, contributing to quicker decision-making.
Enhanced Transparency and Consistency: Promotes transparency and consistency in the review of clinical investigations, bolstering the collaborative effort across Member States.

Research Centers and CROs

Research centers and Contract Research Organizations (CROs) play a vital role in conducting clinical investigations. The document offers them detailed guidance on designing and implementing studies that align with regulatory expectations and scientific rigor.

Design and Conduct of Studies: Facilitates the incorporation of ethical considerations and safety reporting in study designs, ensuring the generation of reliable and meaningful data.
Collaboration Enhancement: Aids in fostering collaborations between industry and research entities, ensuring that studies are conducted efficiently and effectively.

Legal Representatives

Legal representatives are instrumental in ensuring that the sponsor’s obligations under the MDR are met, particularly for non-EU sponsors. MDCG 2021-6 Rev. 1 clarifies their roles and responsibilities, ensuring compliance across the board.

Regulatory Compliance: Guides legal representatives in navigating the MDR requirements, ensuring sponsors fulfill their regulatory duties.

Patients and the General Public

The ultimate beneficiaries of the MDCG 2021-6 Rev. 1 are patients, who gain access to safer and more performance-oriented medical devices.

Access to Innovative Treatments: Enhances patient access to new and innovative medical devices, improving treatment options and patient care.
Enhanced Patient Safety: Prioritizes patient safety through rigorous clinical investigation standards.

Conclusion

The MDCG 2021-6 Rev. 1 marks a significant stride in the EU’s approach to medical device regulation. This document is vital for navigating the complexities of the Medical Device Regulation (EU 2017/745, MDR). It offers a roadmap that impacts a wide range of stakeholders, from manufacturers to regulators and researchers.

Guidance and Collaboration MDCG 2021-6 Rev. 1 details the path for clinical investigations under MDR. It covers regulatory pathways, changes in trials, and usability considerations. This guidance is crucial. It ensures that devices entering the market are both innovative and safe. The document encourages collaboration across the sector, highlighting the shared goal of enhancing patient care.
Impact Across the Board Manufacturers, competent authorities, ethics committees, and others find value in this guidance. It clarifies MDR compliance, aiding in the efficient development and evaluation of medical devices. The emphasis is on using feedback, ensuring ethical conduct, and strategic planning. This collaborative effort advances medical device safety and innovation.
Benefiting Patients and the Public Ultimately, patients and the public stand to gain the most. They benefit from safer, more performance-oriented medical devices. The document fosters an environment where patient care is at the forefront. Innovations in device technology directly enhance patient outcomes and treatment options.
Moving Forward As the regulatory landscape evolves, staying informed and adaptable is key. Stakeholders must use MDCG 2021-6 Rev. 1 insights to meet the MDR’s demands. This commitment to high standards in device development and evaluation will continue to benefit European healthcare.

Written by:

David Tomé

President

Clinical research leader and MedTech entrepreneur with deep expertise in medical devices, IVDs & precision medicine, with global study experience.

Industry Insights & Regulatory Updates

EU AI Act and Medical Devices: What SaMD Developers Need to Know (2026)

EU MDR 2017/745 for Dental Devices: Complete Guide (2026)

FDA QMSR: How the 2026 Regulation Shift Transforms MDSAP Audits and FDA Compliance Inspections

IVDR Annex XIV Performance Studies for Companion Diagnostics: A Step-by-Step Guide 2026

MDR Annex XVI: Regulating Products Without an Intended Medical Purpose Under the MDR

Why Choose an ISO 14155-Compliant MedTech CRO under MDR?

December 3, 2023

In the challenging field of medical device development, particularly under the EU Medical Device Regulation (MDR), selecting the right Contract Research Organization (CRO) is pivotal. A crucial aspect often overlooked is the CRO’s adherence to ISO 14155, the international standard for good clinical practice in clinical trials, which becomes even more significant in light of the MDR’s stringent requirements.

Selecting an ISO 14155-compliant MedTech CRO under EU MDR ensures enhanced data reliability and patient safety. This compliance is key to successful clinical trials, aligning with MDR standards for quality and regulatory adherence, aiding manufacturers in the competitive MedTech field.

Why ISO 14155 Matters in the Context of MDR

ISO 14155, established by the International Organization for Standardization, provides a comprehensive framework for conducting clinical investigations with high ethical and scientific standards, aligning closely with the principles of the MDR. Adherence to ISO 14155 helps compliance with MDR, especially for clinical investigations, by emphasizing the protection of subjects, ensuring data integrity, and maintaining the quality and validity of research findings.

Benefits of Choosing an ISO 14155 CRO for MDR Clinical Investigations

Enhanced Quality and Reliability of Clinical Data: Adhering to ISO 14155 ensures that CROs implement quality control measures and data management practices that align with MDR requirements, leading to more reliable and trustworthy research findings.
Reduced Regulatory Risks and Delays: A CRO with ISO 14155 certification is well-equipped to navigate the MDR landscape, minimizing the risk of non-compliance, which is critical for timely and successful clinical investigations.
Improved Patient Safety: In line with MDR’s focus on patient safety, ISO 14155-compliant CROs prioritize participant well-being, implementing robust risk management and ethical guidelines.
Global Recognition in the MDR Era: ISO 14155 certification holds significant weight under the MDR, enhancing a CRO’s reputation for commitment to quality and compliance.
MDR-Specific Expertise and Experience: CROs compliant with ISO 14155 bring valuable insights and experience in conducting clinical trials that meet both ISO and MDR standards, offering expert guidance throughout the development process.

Conclusion

In the medical device sector, especially under the EU Medical Device Regulation, partnering with a CRO that is compliant with ISO 14155 is a strategic decision for success. MDx, as a CRO adept in both ISO 14155 and MDR requirements, offers a comprehensive approach to ensure patient safety, data integrity, and regulatory compliance. This makes MDx an excellent choice for manufacturers aiming to meet the high standards of the MDR and succeed in the competitive medical device market.

Why Choose MDx as Your Medical Device CRO Partner for ISO 14155 Compliance

MDx stands out as a preferred partner for manufacturers and sponsors in the MDR-regulated environment. Our compliance with ISO 14155 ensures that we are not only aligned with international standards but also adept at navigating the specific requirements of the MDR for clinical investigations. Our team offers:

MDR and ISO 14155 Expertise: Ensuring that your clinical trials meet all regulatory requirements for safety and efficacy.
Commitment to Quality and Integrity: Prioritizing the quality of clinical data, which is essential under the MDR.
Efficient and Cost-Effective Solutions: Streamlining the development process to comply with MDR, reducing delays and costs.
Global Recognition and Network: Enhancing the credibility of your product in the global market, a key aspect in the MDR era.

Written by:

David Tomé

President

Clinical research leader and MedTech entrepreneur with deep expertise in medical devices, IVDs & precision medicine, with global study experience.

Industry Insights & Regulatory Updates

EU AI Act and Medical Devices: What SaMD Developers Need to Know (2026)

EU MDR 2017/745 for Dental Devices: Complete Guide (2026)

FDA QMSR: How the 2026 Regulation Shift Transforms MDSAP Audits and FDA Compliance Inspections

IVDR Annex XIV Performance Studies for Companion Diagnostics: A Step-by-Step Guide 2026

MDR Annex XVI: Regulating Products Without an Intended Medical Purpose Under the MDR

Importing Investigational Devices for Clinical Investigation in Europe | EU MDR Guide

December 3, 2023

Importing investigational devices into Europe under the EU MDR is a complex process that requires strict compliance with regulatory provisions before a clinical investigation can begin. The Medical Device Regulation (MDR) establishes rigorous rules for the entry of investigational devices into the European Union, detailing specific obligations for manufacturers and sponsors. Partnering with a specialized Medical Device Contract Research Organization (CRO) ensures a seamless pathway to compliance and successful device importation.

Essential MDR Provisions for Investigational Device Importation

The MDR delineates vital requirements for the importation of investigational devices:

Designation of an EU Legal Representative: Non-EU entities must appoint a representative within the EU to ensure adherence to MDR regulations. (See MDR Article 62)
Conformity with Labeling Standards: Labels on investigational devices must comply with MDR stipulations, encompassing usage instructions, risk information, and device safety and performance details. Compliance with specific language and symbol requirements is essential. (See MDR Annex I Chapter III)
Demonstration of compliance with the applicable GSPR: This encompasses, when applicable, conducting technical and biological safety assessments, along with pre-clinical evaluations. It also involves implementing measures in occupational safety and accident prevention, all while considering the current state of the art. (See MDR Article 62.4.l)
Adverse Event Surveillance: Manufacturers and sponsors are obligated to implement a system for tracking and reporting adverse events associated with the investigational device over its entire usage period, adhering to defined adverse event criteria and reporting timelines. (See MDR Article 80)
Compliance with MDR Article 21: Importation must adhere to MDR Article 21, ensuring the free movement of investigational devices within the EU for clinical investigation.

Role of a Medical Device CRO in Investigational Device Importation

A Medical Device CRO offers comprehensive support:

Regulatory Guidance: CROs provide deep insights into MDR complexities and keep abreast of regulatory updates.
Labeling Assistance: They ensure investigational device labeling is in full compliance with MDR.
Adverse Event Reporting System Establishment: CROs facilitate setting up compliant adverse event reporting systems.
EU Regulatory Communication: CROs act as liaisons with EU regulatory bodies, managing necessary communications on behalf of manufacturers.
Documentation and Submission Management: From preparing technical documents to managing submissions and responses to EU authorities, CROs play a pivotal role.

Benefits of Collaborating with a Medical Device CRO

Partnering with a CRO offers numerous advantages:

Simplified Regulatory Compliance: CROs handle regulatory complexities, freeing manufacturers to concentrate on development.
Reduced Compliance Risks: Expert advice from CROs minimizes the risks of non-compliance.
Efficient Market Entry: CROs expedite the process of bringing investigational devices to the EU market.
Cost Efficiency: By streamlining the importation process, CROs help in curtailing unnecessary costs.
Expertise Access: CROs offer specialized knowledge in medical device regulation and market entry strategies.

Conclusion

Navigating the MDR for the importation of investigational devices for clinical investigation demands diligent regulatory adherence and strategic planning. Engaging an experienced Medical Device CRO is key to ensuring a compliant and efficient pathway for bringing innovative investigational devices to the EU market.

MDx CRO: Your Strategic Partner for Investigational Device Importation

MDx CRO, a leader in Medical Device CRO services, excels in assisting sponsors and manufacturers through the MDR’s complexities. Our team, proficient in the nuances of the MDR, provides end-to-end support, ensuring your investigational devices are compliantly and effectively introduced into the European market.

With MDx CRO, you gain a partner committed to a compliant, streamlined, and successful introduction of your investigational devices in the EU. Contact us to discover how our expertise can enhance your clinical investigation endeavors.

*MDx offers assistance with the importation of investigational devices. MDx’s range of services does not include acting as an economic operator importer as defined under Article 13 of the EU MDR.

Written by:

David Tomé

President

Clinical research leader and MedTech entrepreneur with deep expertise in medical devices, IVDs & precision medicine, with global study experience.

Industry Insights & Regulatory Updates

EU AI Act and Medical Devices: What SaMD Developers Need to Know (2026)

EU MDR 2017/745 for Dental Devices: Complete Guide (2026)

FDA QMSR: How the 2026 Regulation Shift Transforms MDSAP Audits and FDA Compliance Inspections

IVDR Annex XIV Performance Studies for Companion Diagnostics: A Step-by-Step Guide 2026

MDR Annex XVI: Regulating Products Without an Intended Medical Purpose Under the MDR

Importing IVDs for Performance Studies | EU IVDR Guide

December 3, 2023

The In Vitro Diagnostic Medical Devices Regulation (IVDR) has introduced a stringent regulatory framework for the importation of In Vitro Diagnostic Medical Devices (IVDs) into the European Union (EU) under the IVDR. This framework imposes specific requirements on sponsors and manufacturers who intend to import IVDs for performance studies. To ensure compliance and facilitate a smooth importation process, engaging an experienced IVD CRO (Contract Research Organization) can be invaluable.

IVDR Article 19 is relevant to the importation of IVDs for performance studies in that it establishes the right of sponsors and manufacturers to import IVDs into the EU for the purpose of conducting performance studies. However, it is important to note that the IVDR also imposes certain requirements on the importation of IVDs for performance studies.

Importing IVDs for Performance Studies

The are several key requirements for importing IVDs for performance studies under EU IVDR:

Appointment of a Legal Representative: Non-EU sponsors must appoint a legal representative within the EU fro their clinical performance studies. This representative is responsible for ensuring compliance with the IVDR sponsor’s obligations , and shall be the addressee for all communications with the sponsor provided for in this Regulation. (IVDR Article 58)
Labeling Requirements: Labeling must be in accordance with the IVDR’s labeling requirements, which include information on the intended use, risks, and performance of the IVD. Specific requirements include appropriate language, symbols, and hazard indications.
Adverse Event Reporting: Sponsors and manufacturers must establish and maintain systems for reporting adverse events associated with the IVD throughout its lifecycle. This includes defining what constitutes an adverse event and adhering to specified timelines for reporting. (IVDR Article 82)
Compliance with IVDR Article 19: Ensure that the importation of IVDs for performance studies adheres to the principles of freedom of movement. (IVDR Article 19)

The Role of an IVD CRO in Importation

An experienced IVD CRO can provide comprehensive support to sponsors and manufacturers throughout the importation process, ensuring adherence to the IVDR’s requirements and streamlining the regulatory pathway.

Regulatory Expertise: IVD CROs possess in-depth knowledge of the IVDR, including staying updated on changes or updates to the regulation, and can guide sponsors and manufacturers through the complex regulatory landscape.
Labeling Review: CROs can assist in reviewing and preparing labeling in accordance with the IVDR’s requirements.
Adverse Event Reporting Procedures: CROs can assist in establishing and implementing adverse event reporting procedures that comply with the IVDR’s requirements.
Communication and Representation: CROs can effectively communicate with EU authorities, representing sponsors and manufacturers during interactions and negotiations, and act as intermediaries for any necessary correspondence.
Documentation Preparation: CROs can assist in preparing and compiling the necessary documentation, including technical files, risk assessments, and labeling.
Submission and Review Management: CROs can manage the submission process, ensuring timely and accurate submissions to EU authorities and addressing any review comments promptly.

Benefits of Engaging an IVD CRO

Engaging an IVD CRO offers several significant benefits for sponsors and manufacturers:

Reduced Regulatory Burden: CROs take on the regulatory burden, allowing sponsors and manufacturers to focus on their core research activities.
Enhanced Compliance: CROs’ expertise helps minimize the risk of non-compliance, preventing delays and potential penalties.
Streamlined Importation Process: CROs facilitate a smooth and efficient importation process, expediting the availability of IVDs for performance studies.
Reduced Costs: CROs can help optimize the importation process, minimizing unnecessary costs and maximizing resource utilization.
Access to Expertise: CROs provide access to a team of experienced professionals with specialized knowledge in IVD regulation.

Conclusion

Importing IVDs for performance studies under the IVDR requires careful consideration of the regulatory landscape and adherence to stringent requirements. Engaging an experienced IVD CRO can provide invaluable support to sponsors and manufacturers, ensuring compliance, streamlining the importation process, and ultimately facilitating the development of innovative IVDs that benefit patient care.

MDx CRO: Your Partner in importation of IVDs for performance studies

MDx CRO is a leading provider of IVD CRO services, with a proven track record of success in helping sponsors and manufacturers navigate the IVDR regulatory landscape. Our team of experts possesses in-depth knowledge of the IVDR and can provide comprehensive support throughout the importation process. With specific examples of our past successes, we demonstrate our expertise and experience in the field.

With MDx CRO as your partner, you can rest assured that your IVD importation process will be compliant, efficient, and cost-effective. Contact us today to learn more about how we can help you bring your innovative IVDs to the European market.

*MDx offers assistance with the importation of devices for performance studies. MDx’s range of services does not include acting as an economic operator importer as defined under Article 13 of the EU IVDR.

Written by:

David Tomé

President

Clinical research leader and MedTech entrepreneur with deep expertise in medical devices, IVDs & precision medicine, with global study experience.

Industry Insights & Regulatory Updates

EU AI Act and Medical Devices: What SaMD Developers Need to Know (2026)

EU MDR 2017/745 for Dental Devices: Complete Guide (2026)

FDA QMSR: How the 2026 Regulation Shift Transforms MDSAP Audits and FDA Compliance Inspections

IVDR Annex XIV Performance Studies for Companion Diagnostics: A Step-by-Step Guide 2026

MDR Annex XVI: Regulating Products Without an Intended Medical Purpose Under the MDR

The Role of a IVDR Legal Representative in Clinical Performance Studies

December 3, 2023

In the field of medical device regulation, the European Union’s In Vitro Diagnostic Medical Devices Regulation (IVDR) exemplifies the EU’s commitment to patient safety and high standards of device performance. Central to this regulation is Article 58, which stipulates the requirement for non-EU sponsors of clinical performance studies to appoint a legal representative within the EU. This provision is integral to ensuring these studies align with the EU’s stringent regulatory standards. This article highlights the vital role of the legal representative under Article 58 of the IVDR in ensuring compliance of clinical performance studies.

Understanding IVDR Article 58

The IVDR plays a crucial role in safeguarding the safety and performance of in vitro diagnostic medical devices (IVDs). Article 58 mandates the appointment of a legal representative in the EU for clinical performance studies initiated by sponsors outside the EU. This requirement is not just a procedural step; it is a strategic measure to ensure adherence to the EU’s rigorous regulatory framework.

Role and Responsibilities of the IVDR Legal Representative following article 58.

The legal representative serves as an essential link between the sponsor and the EU’s regulatory bodies. Their responsibilities include:

Communication Facilitator: Acting as the main contact for EU regulatory authorities, addressing questions and ensuring effective communication.
Regulatory Compliance: Ensuring that the clinical performance studies comply with all relevant IVDR requirements, encompassing ethical standards, patient safety, and data protection.
Documentation Management: Maintaining comprehensive and accurate records of the study, including protocols, reports, and patient data.
Sponsor Representation: Representing the sponsor in interactions with EU authorities and providing expert guidance throughout the study process.
Documentation Submission and Review: Assisting in the preparation and submission of necessary documentation to EU authorities for timely and thorough review.

Advantages of Engaging a IVDR Legal Representative in Clinical Performance Studies

Appointing a legal representative offers several benefits:

Regulatory Burden Reduction: They possess an in-depth understanding of the IVDR, allowing sponsors to focus on research without the complexities of regulation.
Compliance Enhancement: Their expertise ensures studies adhere to all IVDR requirements, minimizing the risk of non-compliance.
Effective Regulatory Communication: They facilitate smooth interactions with EU authorities, overcoming potential language barriers.
Risk Mitigation: Early identification and resolution of compliance issues prevent delays.
Expedited Approval Processes: Their knowledge of the regulatory landscape can accelerate the approval process, bringing IVDs to the market more swiftly.

The Intersection with ISO 20916

In the realm of in vitro diagnostic medical devices (IVDs), the intersection of the European Union’s IVDR, particularly Article 58, with ISO 20916:2019 is a pivotal point for ensuring the highest standards in clinical performance studies. ISO 20916:2019 provides a comprehensive framework for the design, conduct, and reporting of these studies, ensuring their validity, reliability, and compliance with international ethical and regulatory requirements.

This intersection is critical for several reasons:

Harmonization of Standards: ISO 20916:2019 complements the IVDR by offering an internationally recognized standard for clinical performance studies. This harmonization is particularly beneficial for non-EU sponsors required to appoint a legal representative under Article 58 of the IVDR. By aligning their studies with ISO 20916, sponsors can ensure global acceptance of their data while meeting EU-specific regulatory requirements.
Enhanced Regulatory Compliance: The legal representative’s role, as outlined in Article 58, extends to ensuring that the clinical performance studies not only comply with the IVDR but also adhere to the quality and reliability standards set by ISO 20916. This dual compliance enhances the credibility and acceptability of the study outcomes.
Quality and Safety Assurance: ISO 20916’s focus on rigorous methodology, data integrity, and ethical considerations strengthens the safety and performance evaluation of IVDs. When combined with the IVDR’s emphasis on patient safety and effective regulatory oversight, this leads to a more robust and trustworthy assessment of IVDs.
Streamlined Approval Process: Understanding and implementing the requirements of ISO 20916 can facilitate a smoother approval process within the EU regulatory framework. The legal representative’s expertise in both ISO 20916 and the IVDR can expedite the review and approval of clinical performance studies, ultimately accelerating the time-to-market for innovative IVDs.

In conclusion, the integration of ISO 20916:2019 into the IVDR framework, especially under the auspices of Article 58, represents a strategic and operational synergy. It ensures that clinical performance studies of IVDs not only meet the EU’s stringent regulatory requirements but also align with global best practices, paving the way for advanced medical technologies.

Selecting an Appropriate Legal Representative in IVD.

Choosing the right legal representative is critical for the success of clinical performance studies:

Experience: A proven history of managing IVDR clinical performance studies successfully is essential.
Expertise: In-depth knowledge of the IVDR is crucial.
Communication Skills: They should emphasize clear and consistent communication with the sponsor.
Networking Abilities: A robust network within the EU regulatory framework is advantageous for insights and connections.

Conclusion

The appointment of a legal representative under Article 58 of the IVDR is a crucial step for non-EU sponsors aiming to conduct clinical performance studies in the EU. This role is more than a regulatory requirement; it is a key element in navigating the EU’s regulatory landscape and ensuring compliance with the IVDR’s strict standards. With the appropriate legal representative, sponsors can focus on their primary objective: advancing medical science and improving patient outcomes through innovative in vitro diagnostics.

Written by:

Carlos Galamba

CEO

Senior regulatory leader and former BSI IVDR reviewer with deep experience in CE marking high-risk IVDs, companion diagnostics, and IVDR implementation.

Industry Insights & Regulatory Updates

EU AI Act and Medical Devices: What SaMD Developers Need to Know (2026)

EU MDR 2017/745 for Dental Devices: Complete Guide (2026)

FDA QMSR: How the 2026 Regulation Shift Transforms MDSAP Audits and FDA Compliance Inspections

IVDR Annex XIV Performance Studies for Companion Diagnostics: A Step-by-Step Guide 2026

MDR Annex XVI: Regulating Products Without an Intended Medical Purpose Under the MDR